There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viridian Therapeutics (VRDN – Research Report), Masimo (MASI – Research Report) and Johnson & Johnson (JNJ – Research Report) with bullish sentiments.
Viridian Therapeutics (VRDN)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Viridian Therapeutics today and set a price target of $36.00. The company’s shares closed last Tuesday at $19.61.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of
Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $38.20, representing a 96.1% upside. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $46.00 price target.
See today’s best-performing stocks on TipRanks >>
Masimo (MASI)
In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Masimo, with a price target of $145.00. The company’s shares closed last Tuesday at $130.10.
According to TipRanks.com, Thibault is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Masimo with a $128.33 average price target.
Johnson & Johnson (JNJ)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson yesterday and set a price target of $181.00. The company’s shares closed last Tuesday at $160.98.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $177.67, a 10.8% upside from current levels. In a report issued on February 20, Cantor Fitzgerald also maintained a Buy rating on the stock with a $215.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRDN:
- Viridian Therapeutics names Jennifer Tousignant chief legal officer
- Insider Trading: Viridian (NASDAQ:VRDN) Sees Huge Insider Buy
- Viridian Therapeutics price target lowered to $39 from $40 at Wedbush
- Viridian Therapeutics 7.14M share Spot Secondary priced at $21.00
- Viridian announces offering of common stock, Series B preferred stock
